408 related articles for article (PubMed ID: 38279263)
1. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
[TBL] [Abstract][Full Text] [Related]
2. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
3. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
4. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
6. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies for cancer therapy by ATR inhibitors.
Yano K; Shiotani B
Cancer Sci; 2023 Jul; 114(7):2709-2721. PubMed ID: 37189251
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract][Full Text] [Related]
9. Targeting replication stress in cancer therapy.
da Costa AABA; Chowdhury D; Shapiro GI; D'Andrea AD; Konstantinopoulos PA
Nat Rev Drug Discov; 2023 Jan; 22(1):38-58. PubMed ID: 36202931
[TBL] [Abstract][Full Text] [Related]
10. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
11. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ATR-CHK1 signaling by ubiquitination of CLASPIN.
Zhu X; Zheng XY; Gong P; Xu X
Biochem Soc Trans; 2022 Oct; 50(5):1471-1480. PubMed ID: 36196914
[TBL] [Abstract][Full Text] [Related]
13. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
14. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
15. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
16. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
18. Src family kinases maintain the balance between replication stress and the replication checkpoint.
Miura T; Fukumoto Y; Morii M; Honda T; Yamaguchi N; Nakayama Y; Yamaguchi N
Cell Biol Int; 2016 Jan; 40(1):16-26. PubMed ID: 26194897
[TBL] [Abstract][Full Text] [Related]
19. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
Mutat Res; 2023; 827():111834. PubMed ID: 37531716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
